Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to today

From X

@StableBread 4 clicks

Fajasy on X

At CAD$1.98/share (October 23 close), you’re paying US$214-265M for Levack, the flagship restart project of Magna Mining $MGMNF (TSX: $NICU), or 62-76% of the enterprise value. On the 336.57M diluted count, Magna’s market cap is US$476M, and here’s how it breaks down: → Cash, incl. option proceeds: US$130M (CAD$0.54/share) → McCreedy West, the producing mine: US$28-43M (CAD$0.11-0.18/share) → Crean Hill, the permitted nickel mine: US$54-90M (CAD$0.22-0.37/share) → Levack, R2 (a high-grade zone at Levack), and the rest (implied): US$214-265M (CAD$0.89-1.10/share) For McCreedy West, I valued 3-5 years of margin, discounted at 8%. For Crean Hill, I applied 0.3-0.5x the US$179M after-tax NPV in its October 20 pre-feasibility study. To estimate how much Levack has to produce each year to justify the CAD$1.98 share price, I assumed: → Margin: US$1.85/payable lb before taxes. I started with McCreedy West’s Q2 cash margin of US$1.41/lb, subtracted US$0.42/lb of H1 sustaining capital, and added back the US$0.86/lb the precious metals stream took in Q2. CEO Jason Jessup said most of the tons in Levack’s October 7 preliminary economic assessment (PEA) would come from the contact zones, which I assume sit outside the stream, since the PEA release doesn’t say how much ore the stream covers. → Timing: 7.3 years of output starting in mid-2028, per the PEA. → Taxes: 27% of the value, the share Levack’s PEA loses to taxes. → Discount rate: 8%. On these assumptions, US$214-265M requires 32-40M payable lbs/year from Levack before restart capital (the upfront spending to rebuild and reopen the mine). The PEA’s CAD$70.1M of initial capital adds ~7.5M lbs/year to the requirement, but pre-commercial cash flow and tax credits cut the net funding need to CAD$8.6M, or ~1M lbs/year. Jessup had said Levack could produce 2-3x McCreedy West’s output. The PEA plans 36.8M payable lbs/year from mid-2028 to 2035, ~2.2x McCreedy West’s 17M lbs guidance midpoint. So at Q2 margins, CAD$1.98 assumes close to the PEA’s output, which leaves out R2. But 2.1M of the PEA’s 5.75M short tons are inferred resources (from more widely spaced holes), so over a third of the plan rests on less certain tonnes. However, a 10% higher realized price adds US$0.60/lb to the margin and cuts the requirement to 24-30M lbs/year, well below the PEA’s 36.8M. Since Q2, copper is up 8.3% from Magna’s average ($6.54/lb vs. $6.04), while nickel is down 13.5% ($7.12 vs. $8.23). Nickel is 46.0% of the PEA’s revenue and copper 34.8%, so for Levack, nickel’s drop outweighs copper’s gain. In other words, higher copper prices alone won’t lower what Levack has to deliver. Nickel has to recover too.

Investor Letters

All letters

Altria: Dutiful

Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.

MO $130B
Invariant 2 clicks

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

ABR $2.2B
John Hempton's Newsletter 3 clicks

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

VRRM $404M
The Oak Bloke 2 clicks

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $20B
Stock Thoughts 4 clicks

Microsoft's AI Boom Has A Cost

Microsoft’s Azure grew 48% as AI monetization accelerated, but doubled CapEx, largely for CPUs and GPUs, reduced quarterly free cash flow…

MSFT $3.9T
Yiannis Zourmpanos 2 clicks

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $465B
Cestrian Capital Research 3 clicks

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $108B
Cestrian Capital Research 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 69 of 269

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.